Literature DB >> 1948130

In vitro data supporting interferon plus cytotoxic agent combinations.

D D Von Hoff1.   

Abstract

The human tumor cloning system is an in vitro assay that has been used to predict response of patients' tumors to conventional antineoplastic agents as well as to biologic agents. In addition, the assay has been used to screen for antitumor activity of newly discovered cytotoxics and biologics. The purpose of the present series of studies was to determine whether there are combinations of interferon alfa (rIFN-alpha) and cytotoxic agents that demonstrate synergism in this in vitro assay. In these studies, there was significant synergism for doxorubicin + rIFN-alpha, fluorouracil + rIFN-alpha, and etoposide + rIFN-alpha. Synergism was noted across a wide variety of tumor types. Results from these in vitro studies suggest that selected combinations of interferon + cytotoxic agents should be tested in clinical trials.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1948130

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  6 in total

1.  Recombinant leukocyte interferon, doxorubicin, and 5FUDR in patients with hepatocellular carcinoma-A phase II trial.

Authors:  Lynn G Feun; Christopher O'Brien; Enrique Molina; Miguel Rodriguez; Lenox Jeffers; Eugene R Schiff; Angela Marini; Niramol Savaraj; Bach Ardalan
Journal:  J Cancer Res Clin Oncol       Date:  2003-01-09       Impact factor: 4.553

2.  5-Fluorocytosine-mediated apoptosis and DNA damage in glioma cells engineered to express cytosine deaminase and their enhancement with interferon.

Authors:  Z H Wang; S Samuels; M A Gama Sosa; E H Kolodny
Journal:  J Neurooncol       Date:  1998-02       Impact factor: 4.130

3.  Phase I study of combined alpha interferon, alpha difluoromethylornithine (DFMO), and doxorubicin in advanced malignancy.

Authors:  V Ganju; J H Edmonson; J C Buckner
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

4.  Etoposide, leucovorin, 5-fluorouracil and interferon alpha-2b in elderly gastric cancer patients: a pilot study.

Authors:  S Cascinu; A Fedeli; G Catalano
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

5.  Five-day infusional fluorodeoxyuridine with oral leucovorin and escalating doses of interferon alpha-2b: a phase I study.

Authors:  E E Vokes; S M O'Brien; N J Vogelzang; R L Schilsky; M J Ratain
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

6.  Phase II study of etoposide and alpha-interferon in patients with advanced measurable colorectal carcinoma.

Authors:  J A Ajani; J L Abbruzzese; A B Markowitz; Y Z Patt; K Daugherty
Journal:  Invest New Drugs       Date:  1993-02       Impact factor: 3.850

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.